Read + Share
Kimura M, Usami E, Teramachi H, Yoshimura T, et al. Risk-benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line
Treatment in Metastatic Colorectal Cancer. Anticancer Res 2021;41:3091-3097.
PMID: 34083302
|
 |
|
Kimura M, Usami E, Teramachi H, Yoshimura T, et al. Risk-benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line
Treatment in Metastatic Colorectal Cancer. Anticancer Res 2021;41:3091-3097.
PMID: 34083302
|
|
|
|